Company newsCompany release
CRISPR Therapeutics presents Phase 1b CTX310 data at AHA 2026
A single-course treatment with CTX310 produced mean reductions from baseline of 65% in ANGPTL3 and 63% in triglycerides at Day 30 in patients with severe hypertriglyceridemia.
GetSignal
On November 9, 2026, CRISPR Therapeutics presented clinical data from its Phase 1b trial of CTX310, an investigational in vivo CRISPR/Cas9 gene editing therapy that acts on ANGPTL3, in a late-breaking oral presentation at the American Heart Association Scientific Sessions 2026. The company said CTX310 was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases.
Key facts
- Mean reduction in ANGPTL3 at Day 30
- 65% from baseline
- Mean reduction in triglycerides at Day 30
- 63% from baseline
- Median baseline triglycerides
- Above 1,000 mg/dL
- Presentation
- Late-breaking oral presentation at AHA Scientific Sessions 2026
Source: The company's release on GlobeNewswire, November 9, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
CRISPR Therapeutics AG first, then the newest- CRISPR Therapeutics appoints Siva Sakhamuri as chief technical officer
CRSP · CRISPR Therapeutics AG · Company release · Nov 2, 2026
- CRISPR Therapeutics CFO Raju Prasad to step down
CRSP · CRISPR Therapeutics AG · Company release · Oct 19, 2026
- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
